New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
10:01 EDTXENT, EPAM, CSGP, TKMR, SMI, MVNR, IMDZ, DSGX, VTSS, SYRG, SEAS, MELA, STAY, CTSO, TSQ, SBLK, PFNXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: CoStar Group (CSGP) initiated with a Buy at Goldman... CytoSorbents (CTSO) initiated with a Buy at H.C. Wainwright... Descartes Systems (DSGX) initiated with an Overweight at Barclays... EPAM Systems (EPAM) initiated with a Sell at Monness Crespi... Extended Stay America (STAY) resumed with an Overweight at JPMorgan... Immune Design (IMDZ) initiated with a Buy at Jefferies... Intersect ENT (XENT) initiated with an Outperform at Leerink... MELA Sciences (MELA) initiated with a Buy at H.C. Wainwright... Mavenir Systems (MVNR) coverage resumed with a Buy at BofA/Merrill... Pfenex (PFNX) initiated with a Buy at Mizuho... SeaWorld (SEAS) initiated with an Outperform at Credit Suisse... Semiconductor Manufacturing (SMI) initiated with an Overweight at Barclays... Star Bulk Carriers (SBLK) initiated with an Overweight at Evercore... Synergy Resources (SYRG) initiated with a Buy at Canaccord... Tekmira (TKMR) initiated with an Outperform at Leerink... Townsquare Media (TSQ) initiated with a Buy at BofA/Merrill... Vitesse (VTSS) initiated with an Outperform at Northland.
News For CSGP;CTSO;DSGX;EPAM;STAY;IMDZ;XENT;MELA;MVNR;PFNX;SEAS;SMI;SBLK;SYRG;TKMR;TSQ;VTSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
17:10 EDTPFNXPfenex files to sell 5.23M shares of common stock for holders
Subscribe for More Information
17:09 EDTPFNXPfenex files $120M mixed securities shelf
Subscribe for More Information
10:00 EDTSMIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:23 EDTSMISemiconductor Manufacturing upgraded to Outperform at Bernstein
Bernstein upgraded Semiconductor Manufacturing to Outperform from Market Perform and raised its price target to $5.70 from $5.50. The firm expects the company to benefit from the Chinese government's support of the semiconductor industry and said its different customer base and market exposure shields it from the sluggish smartphone industry.
August 26, 2015
10:17 EDTSTAYMKM Partners' four Lodging stock ideas following the pullback
Subscribe for More Information
07:46 EDTXENTIntersect ENT management to meet with Leerink
Subscribe for More Information
August 25, 2015
08:05 EDTSYRGSynergy Resources appoints James Henderson as CFO
Subscribe for More Information
August 21, 2015
12:40 EDTEPAMEPAM Systems management to meet with William Blair
Subscribe for More Information
August 17, 2015
16:06 EDTSEASSeaWorld names Peter Crage as CFO, names Anthony Esparza Chief Creative Officer
Subscribe for More Information
09:03 EDTXENTIntersect ENT announces 'positive' preliminary PROPEL clinical results
Intersect ENT announced preliminary results of PROGRESS, a prospective, randomized, blinded, multi-center trial to assess the safety and efficacy of the PROPEL mini steroid releasing sinus implant when used following frontal sinus surgery. The study met its primary efficacy endpoint, demonstrating a statistically significant 38% relative reduction in the need for post-operative interventions, such as the need for additional surgical procedures or need for oral steroid prescription, compared to surgery alone. The device placement success rate was 100% and there were no device-related adverse events. As many as one in four patients undergoing surgery for chronic sinusitis suffers from frontal sinus disease. The trial is intended to support an expanded indication for placement of PROPEL mini in the frontal sinuses, which are located behind the eyebrows. PROPEL mini is currently indicated for placement in the ethmoid sinuses, located just behind the bridge of the nose.
08:04 EDTPFNXPfenex awarded HHS contract valued at up to $143.5M
Pfenex announced it has signed a five year, cost plus fixed fee contract valued at up to $143.5M with the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services, for the advanced development of Px563L, a mutant recombinant protective antigen anthrax vaccine. Under the contract, the base period will fund activities related to current Good Manufacturing Practice (cGMP) manufacturing of drug product and a Phase 1a clinical study. Milestone-based option periods include completion of a Phase 1b clinical study, a Phase 2 clinical study and non-clinical efficacy studies as well as manufacturing technology transfer and optimization, process and analytical method validation and consistency lot manufacture. Pfenex believes the successful completion of the activities under this contract could lead to a procurement contract for supply of Px563L to the Strategic National Stockpile.
07:01 EDTTSQTownsquare Media to acquire North American Midway Entertainment for $75.5M
Townsquare Media has entered into a definitive purchase agreement to acquire North American Midway Entertainment, a provider of rides, games and food concessions in North America, for approximately $75.5M, subject to certain working capital and other adjustments. In connection with the acquisition, NAME's management team will join Townsquare and will continue to lead the business as a part of Townsquare's Live Events division. The company expects this acquisition will be accretive to 2015 pro forma EPS. Under the terms of the definitive agreement, Townsquare will acquire all of the issued and outstanding membership interests of NAME from the shareholders of the Heartland Group LLC for total consideration of $75.5M, $5.5M of which will be comprised of Townsquare Class A common stock. Townsquare expects to finance the remaining consideration through a combination of secured debt financing and cash on hand. The acquisition has been approved by the Boards of Directors of both companies, and is expected to close in the third quarter.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use